)
)
)
Intragel Therapeutics
Intragel Therapeutics, a clinical-stage company revolutionizing long-acting injectables (LAIs) through our proprietary SRGel platform, a safe fatty acid based, solvent-free, injectable gel compatible with small molecules, peptides, and biologics. The SRGel platform is clinically validated, scalable, and enables controlled drug release from days to months. It supports a robust pipeline including programs in oncology (clinical), hepatic disease (pre-clinical), obesity (R&D), and other indications.
Our lead asset, TumoCure, is a LAI cisplatin-SRGel formulation for head and neck cancer (SCCHN) patients’ ineligible for systemic chemotherapy, exhibiting very low survival rate. TumoCure has demonstrated safety and preliminary efficacy in a Phase Ib trial in palliative setup of chemo- and radio-resistant patients, with 6 out of 7 patients showing clinical benefit and no serious adverse events.
Address
NazarethIsrael
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)